Drug Profile
Aminolevulinic acid - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Alternative Names: ALA; ALA PDT; Aminolevulinic acid hydrochlorideLatest Information Update: 23 Mar 2022
Price :
$50
*
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Condylomata acuminata
- Phase II Cervical intraepithelial neoplasia; Human papillomavirus infections
- Phase I/II Acne vulgaris
- No development reported Basal cell cancer; Glioma
Most Recent Events
- 06 Dec 2021 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical completes a phase I trial in Acne Vulgaris in China (Topical, Powder) (NCT04044898)
- 22 Jan 2021 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical initiates phase I trial for Acne Vulgaris in China (Topical, Powder) (NCT04044898)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Basal-cell-cancer in China